Filtered By:
Therapy: Antiviral Therapy
Vaccination: Pneomococcal Vaccine
This page shows you your search results in order of date.
Order by Relevance | Date
Total 16 results found since Jan 2013.
Risk of infections in patients with pemphigus treated with rituximab versus azathioprine or mycophenolate mofetil: A large-scale global cohort study
CONCLUSION: Within the first 12 months after treatment, patients under rituximab experience an elevated risk of COVID-19, parasitic and CMV infections. Rituximab is associated with pneumonia, osteomyelitis, and viral diseases even beyond the first year after therapy. Pneumococcal vaccine and suppressive antiviral therapy should be considered even one year following therapy. No signal for elevated risk of tuberculosis, hepatitis B virus reactivation, pneumocystis jiroveci pneumonia, and progressive multifocal leukoencephalopathy.PMID:36763798 | DOI:10.1093/bjd/ljac118
Source: The British Journal of Dermatology - February 10, 2023 Category: Dermatology Authors: Khalaf Kridin Noor Mruwat Kyle T Amber Ralf J Ludwig Source Type: research
Molecular mechanisms involved in pathogenicity of SARS-CoV-2: Immune evasion and implications for therapeutic strategies
Biomed Pharmacother. 2022 Jun 30;153:113368. doi: 10.1016/j.biopha.2022.113368. Online ahead of print.ABSTRACTSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused the outbreak of unusual viral pneumonia that emerged in late 2019 in the city of Wuhan, China. Since then, because of its high transmission and pathogenic potential it spread almost all over the world causing the pandemic, as an extraordinary threat to the world public health. Rapid activation of a well-orchestrated and functional immune system with its both arms innate and adaptive immune response is pivotal to eradication of the disease caused by...
Source: Biomedicine and pharmacotherapy = Biomedecine and pharmacotherapie - July 6, 2022 Category: Drugs & Pharmacology Authors: Hatixhe Latifi-Pupovci Source Type: research
A Case of Heart Transplantation for Fulminant Myocarditis After ChAdOx1 nCoV-19 Vaccination
J Korean Med Sci. 2022 Apr 4;37(13):e104. doi: 10.3346/jkms.2022.37.e104.ABSTRACTVaccines have become the mainstay of management against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (coronavirus disease 2019; COVID-19) in the absence of effective antiviral therapy. Various adverse effects of COVID-19 vaccination have been reported, including cardiovascular complications such as myocarditis or pericarditis. Herein, we describe clinical records of a 63-year woman with fulminant myocarditis following ChAdOx1 nCoV-19 vaccination that was salvaged by heart transplantation. She complained chest pain, na...
Source: J Korean Med Sci - April 5, 2022 Category: General Medicine Authors: Seok Hyun Kim Soo Yong Lee Ga Yun Kim Ji Soo Oh Jeongsu Kim Kook Jin Chun Min Ho Ju Chee-Hoon Lee Yeo-Jeong Song Joo-Young Na Source Type: research
Evaluation of effectiveness, safety and cost-benefit of the 23- valent pneumococcal capsular polysaccharide vaccine for HIV-Infected patients
CONCLUSION: Our study results showed that PPV23 can be safely and effectively administered to HIV-1 infected individuals and effectively preventing Streptococcal pneumonia. Considering the cost-benefit of vaccination among HIV-infected persons, as it has been reported in our study, it is necessary to promote the widespread use of the vaccine among HIV-infected persons in the future.PMID:34857419 | DOI:10.1016/j.vaccine.2021.11.058
Source: Vaccine - December 3, 2021 Category: Allergy & Immunology Authors: Xiaobai Zou Jianmei He Jun Zheng Mengran Liang Jinjin Gao Jianwen Huang Yang Jiang Yonglin Jiang Xi Chen Source Type: research
